Leprosy Vaccine Successfully Developed

After twelve years of research, a leprosy vaccine has been successfully developed and is being readied for trial. First the vaccine will be manufactured in a large enough quantity for further testing to ensure there are no side effects. The next step will be toxicology studies, which are scheduled to take place later this year. Then the vaccine will be ready for phase I clinical trials in healthy human volunteers in 2015 and 2016.

The vaccine development project has been led by American Leprosy Missions, the nation’s oldest anti-leprosy organization, and the Infectious Disease Research Institute (IDRI) in Seattle, Washington. Since 2002, American Leprosy Missions has invested $4 million into vaccine research and development.

For more information: